Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | STS | P08842 | 10/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17713753 | 1.00 | HPGD (0.49) | HPGDSTSRECQLPTPN2PTPN1 | |
| SCHEMBL17713748 | 1.00 | HPGD (0.49) | HPGDSTSRECQLPTPN2PTPN1 | |
| SCHEMBL17713715 | 0.85 | LMNA (0.33) | HPGDSTS | |
| SCHEMBL17713713 | 0.85 | LMNA (0.33) | HPGDSTS | |
| SCHEMBL4407329 | 0.83 | HPGD (0.50) | HPGDSTSRECQLPTPN2PTPN1 | |
| SCHEMBL21990901 | 0.78 | HPGD (0.50) | HPGDSTSRECQLPTPN2PTPN1 | |
| SCHEMBL897784 | 0.77 | HPGD (0.48) | HPGDSTSRECQLGPR119EPHX1 | |
| SCHEMBL19626321 | 0.76 | HPGD (0.60) | HPGDSTSRECQLPTPN2PTPN1 | |
| SCHEMBL16212857 | 0.76 | BTK (0.45) | EPHX1KMT2A | |
| SCHEMBL16212853 | 0.76 | BTK (0.45) | EPHX1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3317271-B1 | INHIBITORS OF EZH2 (ENHANCER OF ZESTE HOMOLOG 2) | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-05-13 | — | — | EP | disclosed |
| EP-3317271-B1 | INHIBITORS OF EZH2 (ENHANCER OF ZESTE HOMOLOG 2) | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-05-13 | — | — | EP | disclosed |
| US-20180162845-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-06-14 | — | — | US | disclosed |
| US-20180162845-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-06-14 | — | — | US | disclosed |
| US-20180162845-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-06-14 | — | — | US | disclosed |
| US-20170334891-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| US-20170334891-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| US-20170334891-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| WO-2017002064-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-05 | — | — | WO | disclosed |
| WO-2016066697-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334891-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, BMI1, EZH1 | HPGD 2028/4885STS 4071/4885RECQL 3615/4885 |
| US-20180162845-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, BMI1, EZH1 | HPGD 2028/4885STS 4071/4885RECQL 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.